Multisystem proteinopathy due to a homozygous p.Arg159His VCP mutation : a tale of the unexpected by De Ridder, W et al.
ARTICLE
Multisystem proteinopathy due to a homozygous
p.Arg159His VCP mutation
A tale of the unexpected
Willem De Ridder, MD, Abdelkrim Azmi, PhD, Christoph S. Clemen, MD, Ludwig Eichinger, PhD,
Andreas Hofmann, PhD, Rolf Schro¨der, MD, Katherine Johnson, PhD, Ana To¨pf, PhD, Volker Straub, MD, PhD,
Peter De Jonghe, MD, PhD, Stuart Maudsley, PhD, Jan L. De Bleecker, MD, PhD, and Jonathan Baets, MD, PhD
Neurology® 2019;00:1-12. doi:10.1212/WNL.0000000000008763
Correspondence
Dr. Baets
jonathan.baets@
uantwerpen.be
Abstract
Objective
To assess the clinical, radiologic, myopathologic, and proteomic ﬁndings in a patient mani-
festing a multisystem proteinopathy due to a homozygous valosin-containing protein gene
(VCP) mutation previously reported to be pathogenic in the heterozygous state.
Methods
We studied a 36-year-old male index patient and his father, both presenting with progressive
limb-girdle weakness. Muscle involvement was assessed by MRI and muscle biopsies. We
performed whole-exome sequencing and Sanger sequencing for segregation analysis of the
identiﬁed p.Arg159His VCP mutation. To dissect biological disease signatures, we applied
state-of-the-art quantitative proteomics on muscle tissue of the index case, his father, 3 addi-
tional patients with VCP-related myopathy, and 3 control individuals.
Results
The index patient, homozygous for the known p.Arg159His mutation in VCP, manifested
a typicalVCP-relatedmyopathy phenotype, although with a markedly high creatine kinase value
and a relatively early disease onset, and Paget disease of bone. The father exhibited a myopathy
phenotype and discrete parkinsonism, and multiple deceased family members on the maternal
side of the pedigree displayed a dementia, parkinsonism, or myopathy phenotype. Bio-
informatic analysis of quantitative proteomic data revealed the degenerative nature of the
disease, with evidence suggesting selective failure of muscle regeneration and stress granule
dyshomeostasis.
Conclusion
We report a patient showing a multisystem proteinopathy due to a homozygous VCPmutation.
The patient manifests a severe phenotype, yet fundamental disease characteristics are pre-
served. Proteomic ﬁndings provide further insights into VCP-related pathomechanisms.
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Mutations in the valosin-containing protein gene (VCP) are
associated with a rare, dominantly inherited multisystem
proteinopathy (MSP1), which presents with a high diversity
of combinations of phenotypes, including inclusion body
myopathy (IBM), early-onset Paget disease of bone (PDB),
frontotemporal dementia (FTD), amyotrophic lateral scle-
rosis, and parkinsonism.1 At present, >40 diﬀerent heterozy-
gous missense mutations have been reported in VCP.
Important intrafamilial and interfamilial phenotypic variabil-
ity has been noted.1,2 Penetrance of the myopathy phenotype,
PDB, and FTD is estimated at 90%, 50%, and 30%, re-
spectively.3 Onset of muscle weakness occurs during adult-
hood at a mean age of ≈40 to 45 years.3,4
Mutations cluster in the N and D1 domains of the VCP
protein, which is involved in multiple cellular processes and
has a critical role in proteostasis, at the intersection of the
ubiquitin-proteasome system and autophagy.1,5 VCP belongs
to the AAA +ATPase family (ATPases associated with diverse
cellular activities) and uses energy from ATP hydrolysis to
segregate molecules from immobile cellular structures such as
protein complexes or aggregates, membranes, and chromatin,
in conjunction with a collection of cofactors and adaptors.6,7
The exact molecular mechanisms of VCP-related disease re-
main unknown,5 particularly with regard to the tissue-speciﬁc
nature of the disorder and genotype-phenotype correlations.
Here, we present a patient with MSP1 harboring in homo-
zygosity the VCP p.Arg159His mutation, previously reported
to be only pathogenic in the heterozygous state.8–13 Detailed
study of this patient demonstrates that the key MSP1 phe-
notypic characteristics are preserved in case of homozygosity
of this VCP mutation.
Methods
Standard protocol approvals, registrations,
and patient consents
Ethics approval was granted by the relevant local ethics com-
mittees of the participating centers. All participants provided
written informed consent before participation in the study.
Patients and clinical evaluation
The index patient (patient A) and his father (patient B) pre-
sented with unexplained limb-girdle muscular weakness and an
elevated serum creatine kinase (CK) level. No other family
members agreed to be clinically evaluated except for the
mother of patient A. Nerve conduction studies and an EMG
were performed. Muscle MRI was performed on a 1.5T MRI
platform at the Antwerp University Hospital. Cross sections at
the shoulder, abdominal, pelvic, thigh, and calf levels were
assessed on T1-weighted images to evaluate patterns of muscle
involvement. Fatty replacement of muscle was graded accord-
ing to the Mercuri scale.14 Pulmonary function was assessed by
spirometry testing (forced vital capacity) and cardiac function
by ECG and echocardiography. Bone scintigraphy was carried
out, and bone turnover markers in blood (alkaline phospha-
tase) and urine (collagen crosslinks) were evaluated.
Analysis of exome sequencing data
ADNA sample of patient A was submitted to the MRCCentre
for Neuromuscular Diseases Biobank (Newcastle University,
UK). Samples were processed, and whole-exome sequencing
was performed and analyzed by a targeted approach, as de-
scribed previously.15 A candidate variant in VCP (reference
sequence NM_007126) was validated by Sanger sequencing,
and segregation analysis was performed with DNA samples of
patient A, his father (patient B), and his mother.
Muscle biopsies
Muscle biopsies of quadriceps muscle were obtained from
patients A and B, 3 additional patients with a VCP-related
myopathy phenotype, and 3 control individuals (patients C–E
and controls 1–3, clinical details in table 1) and analyzed
following standard histologic and immunohistochemical light
microscopy and electron microscopy protocols.
Patients D and E harboring the p.Gly125Asp mutation are
siblings. Segregation studies conﬁrmed that the mutation was
inherited from the aﬀected father, who also showed a VCP-
related myopathy phenotype. For all of the patients, the
choice to biopsy the quadriceps muscle was similarly based on
clinical and radiologic selective but not yet end-stage in-
volvement of the muscle. Control individuals, biopsied for
subjective myalgia but for whom no clinical, morphologic, or
electrodiagnostic abnormalities had been identiﬁed, were se-
lected on the basis of biopsied muscle, sex, and age.
Sample preparation for iTRAQ labeling and
MS analysis
Proteins were extracted from muscle biopsy specimens of
patients A through E and 3 control individuals in a buﬀer
containing 4% sodium dodecyl sulfate, 100 mmol/L tris-2-
carboxyethyl phosphine, and 50mmol/L Tris, pH 7.8. Lysates
were heated at 95°C for 5 minutes. The extracted proteins
were precipitated with trichloroacetic acid and resolubilized in
8 mol/L urea, 2 mol/L thiourea, and 0.1% sodium dodecyl
sulfate in 50 mmol/L triethylammonium bicarbonate. After
measurement of protein concentrations with theRCDCkit (Bio-
Glossary
CK = creatine kinase; DDR = DNA damage response; FDR = false discovery rate; FDT = frontotemporal dementia; IBM =
inclusion body myopathy; MHC-I = major histocompatibility complex I; MS = mass spectrometer; MSP1 = multisystem
proteinopathy 1; PDB = Paget disease of bone; sIBM = sporadic inclusion bodymyopathy;VCP = valosin-containing protein gene.
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Rad, Hercules, CA), equal amounts of proteins from each lysate
were reduced and alkylated with tris-2-carboxyethyl phosphine
and 5-methyl-methanoethiosulphate, respectively, followed by
trypsin digestion. Peptides from each sample were labeled with
iTRAQ reagents 8plex (Sciex, Concord, Ontario, Canada)
according to the manufacturer’s instructions. The mixed pep-
tides were separated on an oﬄine 2D liquid chromatography
system (Dionex, ULTIMATE 3000; ThermoScientiﬁc, Wal-
tham, MA), consisting of a 15-cm strong cationic exchange
column and a 25-cm nano-RP C18 column. The nanoliquid
chromatography was coupled online to a QExactive-Plus
Orbitrap (ThermoScientiﬁc) mass spectrometer (MS).
Bioinformatic analysis of MS data
The generated raw data from the MS were processed with
the Proteome Discoverer 2.1 (PD2.1) software (Thermo-
Scientiﬁc). For protein identiﬁcation, the search engine
Sequest HT was used against the human UniProt/SwissProt
database with a false discovery rate (FDR) of <1%. The
quantitative proteomics data were then further statistically
analyzed with the Perseus software (version 1.6.1.1).16 Log2-
transformed scaled abundance values generated by the
PD2.1 software were normalized by subtraction of the me-
dian value of the respective column. The complete list of
identiﬁed proteins with the original scaled abundance values
is available from Dryad (table e-1, doi.org/10.5061/dryad.
60fn581). Hierarchical clustering analyses were performed
with euclidean algorithms. Volcano plot analyses assessing
statistical signiﬁcance (t test) together with fold change
(FDR = 0.05, S0 = 0.1) were performed to identify signiﬁ-
cantly dysregulated proteins between patients and controls.
The downstream canonical pathways analysis (ﬁltering
based on p value of overlap) and the upstream regulator
analysis (ﬁltering based on |z score| ≥ 2) as a causal analysis
approach were applied on this set of dysregulated proteins,
using the Ingenuity Pathway Analysis software (Qiagen,
Venlo, the Netherlands).17 To identify signiﬁcant outlier
values in the data of the index patient compared to the other
patients, a Signiﬁcance A analysis in Perseus was per-
formed,18 correcting for multiple hypothesis testing with the
Benjamini-Hochberg FDR (FDR = 0.05).
Immunoblotting
Protein extractions of muscle tissue specimens from patients A
through C and a pooled extract of the control individuals used
for MS analysis were subjected to Western blotting to validate
the MS dataset. Equal amounts of protein were loaded and
separated on 4% to 12% NuPAGE Bis-Tris gels (Life Tech-
nologies, Carlsbad, CA) and transferred onto a polyvinylidene
diﬂuoride membrane (Hybond P; Amersham Biosciences,
Little Chalfont, UK). Membranes were probed with the fol-
lowing selective primary antibodies: anti-PGAM2 (ab97800;
Abcam, Cambridge, UK), anti-LMNB1 (LS-B11184; LSBio,
Seattle, WA), anti-MFF (ab81127; Abcam), anti-GAPDH
(GTX100118; GeneTex, Irvine, CA), and anti-VCP (ab11433,
Abcam and No. 2648; Cell Signaling Technology, Danvers,
MA). Immunodetection was performed using host-speciﬁc
secondary antibodies conjugated with horseradish peroxidase
and the ECL-plus chemiluminescent detection system (Ther-
moScientiﬁc). Western blot results were visualized with the
Amersham Imager 600 digital imaging system and quantiﬁed
with ImageQuant TL software (GE Healthcare Life Sciences,
Table 1 Characteristics of 5 patients with a VCP-related myopathy phenotype and 3 control individuals
Patient A Patient B Patient C Patient D Patient E
Sex Male Male Male Male Female
AAO, y 29 58 53 58 58
VCP
mutation
p.Arg159His
(homozygous)
p.Arg159His p.Arg159His p.Gly125Asp p.Gly125Asp
Presenting
symptoms
Proximal weakness LL Proximal
weakness LL
Proximal weakness LL Proximal weakness LL Proximal weakness LL
Biopsy
(age, y)
Myopathic, rimmed
vacuoles, endomysial
infiltrates (31)
Myopathic,
rimmed
vacuoles (64)
Myopathic, rimmed
vacuoles, endomysial
infiltrates (57)
Myopathic, endomysial
infiltrates, with invasion of
nonnecrotic muscle fibers (58)
Myopathic, endomysial
infiltrates, with invasion of
nonnecrotic muscle fibers (59)
Biopsied
muscle
Quadriceps Quadriceps Quadriceps Quadriceps Quadriceps
Control Control 1 Control 2 Control 3
Sex Male Male Male
Age at present, y 58 66 63
Age at biopsy, y 53 58 59
Biopsied muscle Quadriceps Quadriceps Quadriceps
Abbreviations: AAO = age at onset; LL = lower limbs; VCP = valosin-containing protein gene.
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Marlborough, MA). Quantitative data were normalized to
GAPDH expression levels. Expression data were visualized as
ratios of the respective sample relative to the pooled controls
and compared to log2 iTRAQ expression ratios.
Data availability
Anonymized data not published within the article will be
shared on request by any qualiﬁed investigator.
Results
Genetic findings
A rare variant in VCP was identiﬁed in the exome of patient A.
He appeared to harbor the previously reported heterozygous
pathogenic p.Arg159His (c.476 G>A) mutation in
homozygosity.8–13 DNA of the parents was available for
segregation analysis; both were conﬁrmed to be heterozygous
carriers of the mutation (ﬁgure 1).
Clinical aspects
Patient A, a 36-year-old man of Belgian ancestry, presented
with complaints related to progressive proximal weakness in
the lower limbs that started at the age of 29 years. Clinically,
marked atrophy of lower limb muscles was noted. Nerve
conduction studies yielded normal results; an EMG showed
a mixed pattern of neurogenic or myogenic discharges. Simi-
larly, a diagnostic muscle biopsy performed at that time
appeared to show a mixed pattern of myopathic and apparently
neurogenic abnormalities. Weakness in the limbs progressed to
distal weakness in the lower limbs with a marked foot drop
bilaterally and upper limb, periscapular, and paraspinal weak-
ness. The patient was re-evaluated in our center at the age of 31
years. DNA was sent for whole-exome sequencing, and the
muscle biopsy was reassessed. MRI revealed an asymmetric
pattern of patchy muscle involvement with preferential in-
volvement of paraspinal and lower limb muscles (ﬁgure 2).
At the age of 63 years, patient B (the father) presented with
complaints related to proximal weakness in the lower limbs,
with symptoms slowly progressing since the age of 58 years.
MRI studies revealed a patchy pattern of muscle involvement
similar to that observed in patient A (ﬁgure 2). During follow-
up, the patient noticed an impairment of his right hand
function, which could clinically be attributed to an asymmetric
extrapyramidal syndrome.
The serum CK level for patient B was only mildly elevated
(192 U/L), contrasting with the high CK level for patient A
(1138 U/L). Clinical details for patient A and B are sum-
marized in table 2, and a detailed description of the pattern of
muscle weakness is available from Dryad (table e-2, doi.org/
10.5061/dryad.60fn581).
On thematernal side of the family tree (ﬁgure 1), thematernal
grandfather had exhibited a myopathy phenotype, and many
individuals had been diagnosed with a dementia phenotype or
parkinsonism in the past. Clinical examination of the mother
at the age of 60 years showed no signs of a neuromuscular
disorder, parkinsonism, dementia, or PDB. She refused ad-
ditional technical investigations. In a detailed study of the
Figure 1 Segregation analysis of the VCP p.Arg159His (c.476 G>A) mutation
Only patient A and his parents were clinically examined. Segregation analysis confirmed that both parents were heterozygous carriers of the mutation. The
maternal grandfather of patient Awould have shown amyopathy phenotype anddied at the age of 72 years. Arrow indicates index patient. Half-filled symbols
represent individuals diagnosed with a dementia phenotype in the past; quarter-filled symbol represents an individual diagnosed with parkinsonism. VCP =
valosin-containing protein gene. †For the presumably asymptomatic obligatory carriers, the age at death (years) is mentioned.
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family history, there appeared to be distant consanguinity
between the parents of the index patient (ﬁgure 1).
After identiﬁcation of the VCP p.Arg159His mutation, bone
scintigraphy and baseline studies of bone metabolism led to
the diagnosis of an asymptomatic PDB lesion of vertebra L2
and the ilium on the right side for patient A. For patient B, the
urinary pyridoline/creatinine ratio was borderline increased;
a bone scintigraphy yielded normal results (table 2).
Muscle biopsies
Muscle biopsy of patient A (ﬁgure 3, A–D) showed myo-
pathic features, with increased ﬁber size variation andmultiple
internalized nuclei but also apparently neurogenic features
demonstrated by the presence of angular atrophic ﬁbers.
There was no evident ﬁber-type grouping or grouped atrophy.
Scattered necrotic and regenerating ﬁbers and ﬁbers with
rimmed vacuoles and endomysial inﬂammatory inﬁltrates
were present. Immunostainings demonstrated that in-
ﬂammatory inﬁltrates consisted mainly of CD68+ macro-
phages (ﬁgure 3C). Major histocompatibility complex I
(MHC-I) was regionally upregulated at the sarcolemma
(ﬁgure 3D). Electron microscopy analysis revealed 15- to 18-
nm tubuloﬁlamentous inclusions and rimmed vacuoles.
On the muscle biopsy of patient B, myopathic features con-
sisting of an increased percentage of internalized nuclei and an
increased ﬁber size variation were also noted. A few rimmed
vacuoles were visualized; however, no striking signs of ne-
crosis or regeneration were noted. Ultrastructural analysis
conﬁrmed nonspeciﬁc myopathic features.
Muscle biopsies of patients C through E similarly revealed
mainly myopathic features (table 1), with some scattered
angular atrophic ﬁbers and endomysial inﬂammatory inﬁl-
trates with focal invasion of nonnecrotic muscle ﬁbers (ﬁgure
e-1 available from Dryad, doi.org/10.5061/dryad.60fn581).
Muscle biopsy studies of the control individuals yielded
strictly normal results (table 1).
Proteomic investigation and bioinformatic
interpretation of VCP-related disease
signatures in skeletal muscle
To investigate VCP-related myopathy pathomechanisms in
more detail, an exploratory comparative proteomic study was
performed on skeletal muscle tissue lysates of patients A and B,
3 additional patients (patients C–E) with a VCP-related my-
opathy phenotype, and 3 control individuals. In total, 1,656
iTRAQ-labeled proteins were detected across the 8 samples.
When the dataset was visualized by means of hierarchic clus-
tering, patient A appeared to cluster most closely with patient E
(ﬁgure 4A). To create a general appreciation of VCP-related
disease signatures in VCP-related myopathy muscle ﬁrst,
a volcano plot was generated to compare protein expression
data of the 4 patients harboring a heterozygous mutation in
VCP and the 3 control individuals, followed by functional an-
notation of signiﬁcantly dysregulated proteins. According to
the volcano plot analysis, 390 proteins were signiﬁcantly dys-
regulated, of which 207 were downregulated, in patients
compared to control individuals (ﬁgure 4B). A full list of these
proteins is available from Dryad (table e-3, doi.org/10.5061/
dryad.60fn581). On the basis of the p value of overlap, the top
10 enriched pathways identiﬁed in the canonical pathway
analysis reﬂected mainly downstream consequences of disease
mechanisms, as evident by changes in metabolic pathways in
muscle tissue of patients with a VCP-related myopathy (table 3,
top). The pathway with the lowest (negative) z score (pre-
dicted to be inhibited) was oxidative phosphorylation, and the
one with the highest z score (predicted to be activated) was
sirtuin signaling pathway. The set of predicted potential key
regulators, generated with the Ingenuity Pathway Analysis
upstream regulator analysis, yielded additional pathomechan-
istic insights (full list available from Dryad, table e-4, doi.org/
10.5061/dryad.60fn581). Here, the predicted activation or in-
hibition of multiple upstream regulators (e.g., TWIST1, mir-1,
MEF2C) reﬂected inhibition of myogenesis. Furthermore, in-
ﬂammatory signatures were evident from the analysis, with
multiple cytokines being predicted to be activated, as well as
Figure 2Muscle MRI findings for patients A and B
Axial T1-weighted images are shown for patients A and B (from top down:
shoulder, abdominal, pelvic, thigh, and calf levels). Muscle groups at
shoulder and pelvic levels were relatively spared on imaging. At thigh level,
a patchy, asymmetric pattern of muscle involvement was noted of both
quadriceps andmuscle groups of the posterior compartment. Note the end-
stage involvement of biceps femoris caput brevis muscles (BB) in patient A
and asymmetric involvement of biceps femoris caput longusmuscles (BL) in
patients A and B. At calf level, selective involvement was observed of gas-
trocnemius and soleus muscles. VI = vastus intermedius muscle.
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Table 2 Clinical characteristics of patients A and B
Patient A Patient B
Sex Male Male
Age at present, y 36 66
AAO, y 29 58
Presenting symptoms Proximal weakness LL Proximal weakness LL
Maximal motor capability Walking 300 m Walking 25 m
Walking aids None None
Stairs Cannot climb stairs since age 33 y Cannot climb stairs since age 65 y
Marked muscle cramping Yes No
Cardiac symptoms No No
Age at last examination, y 35 64
Weakness
Proximal
UL Yes No
LL Yes Yes
Distal
UL Yes No
LL Yes Yes
Other Periscapular, paraspinal, abdominal muscles Paraspinal
Skeletal muscle atrophy LL, distal and proximal muscle groups Quadriceps, forearms
Scapular winging Yes, marked No
Fasciculations No No
Reflexes Absent in UL, normal PTR, absent ATR Absent in LL and UL
Pyramidal tract signs No No
Extrapyramidal signs No Mild bradykinesia, rigidity, and
tremor of the right arm
MoCA score 28/30 27/30
Serum CK, U/L 1,138 192
EMG (age, y) Mixed myopathic/neurogenic features; spontaneous
activity with positive sharp waves (30)
Myopathic features; no
spontaneous activity (63)
Resting ECG Normal Normal
Echocardiography Normal Mild left ventricular hypertrophy
Holter monitoring Normal Normal
FVC, % predicted 81 74
Bone scintigraphy Paget lesion of L2 and right ileum Normal
Urinary pyridoline/creatinine (normal values
5.5–69.4 pmol/μmol), pmol/μmol
170 51
Urinary deoxypyridoline/creatinine (normal values
1.0–16.9 pmol/μmol), pmol/μmol
33.2 11.5
Abbreviations: AAO = age at onset; ATR = Achilles tendon reflex; CK = creatine kinase; FVC = forced vital capacity; LL = lower limbs; MoCA =Montreal Cognitive
Assessment; PTR = patellar tendon reflex; UL = upper limbs.
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dysregulation of a key metabolic regulator, PPARGC1A. The
occurrence of oxidative stress in patient tissue was suggested by
the predicted activation of NFE2L2, the keymediator theNrf2-
mediated oxidative stress response, occurrence of endoplasmic
reticulum stress, and the unfolded protein response by the
predicted activation of XBP1. The upstream regulator with the
highest positive z score was KDM5A, a histone demethylase
involved in the DNA damage response (DDR).19
Subsequently, a Signiﬁcance A outlier analysis was performed in
Perseus to search for diﬀerences between the proteomes of
patient A and the heterozygous patients with VCP. This yielded
a short list of 19 proteins that appeared to show signiﬁcant
outlier values (table 3, bottom) for patient A. The top hit was
ZFAND1, a protein involved in the regulation of cytoplasmic
stress granule turnover. Notably, RAD17 is a protein involved in
the DDR, and WDR33 is an RNA-processing protein linked to
mRNA homeostasis. Most of the other proteins, showing a less
signiﬁcant outlier value for the homozygous patient, represent
proteins of the contractile apparatus in skeletal muscle.
Finally, we validated MS data of a discrete set of proteins,
PGAM2, LMNB, and MMF, via Western blot analysis, with
protein expression ratios between patients and pooled con-
trols corroborating the data (ﬁgure 4, C and D). According to
the MS dataset, protein expression levels of VCP were similar
across patients and controls, which was also conﬁrmed by
Western blotting (ﬁgure e-2 available fromDryad, doi.org/10.
5061/dryad.60fn581).
Discussion
We report a patient with MSP1 harboring the p.Arg159His
VCP mutation in homozygosity, previously reported to be
pathogenic in heterozygous state. The index patient presented
with young adult–onset proximal weakness in the lower limbs
resulting after 6 years of evolution in walking distance re-
striction to 300m and inability to climb stairs. In addition, distal
weakness in upper and lower limbs, a marked bilateral foot
drop, and scapular winging are typical clinical features of aVCP-
related myopathy.2 Furthermore, an asymptomatic PDB lesion
was diagnosed. The father of the index patient, heterozygous for
the p.Arg159His mutation, exhibited a myopathy phenotype
with onset at 58 years of age and discrete asymmetric parkin-
sonism. The notion of a dementia or parkinsonism phenotype
in multiple deceased family members and the observation that
multiple obligatory carriers died presumably asymptomatic at
an old age further illustrate the characteristic intrafamilial
phenotypic variability of MSP1, even for the otherwise rather
penetrant myopathy part of the disease spectrum.3
The p.Arg159His mutation has previously been reported to be
pathogenic in the heterozygous state in multiple unrelated fam-
ilies showing intrafamilial and interfamilial phenotypic variability,
encompassing IBM, PDB, FTD, and amyotrophic lateral sclero-
sis, which is typical for MSP1, without complete penetrance.8–13
Muscle MRI revealed an asymmetric and patchy pattern of
muscle involvement in patients A and B, with paraspinal and
Figure 3 Histopathologic findings in the muscle biopsy of patient A
(A) Gomori trichrome staining show-
ing rimmed vacuoles (arrow) in mul-
tiple fibers and a marked fiber size
variation with atrophic fibers fre-
quently being angularly shaped (as-
terisk). (B) Hematoxylin & eosin
staining showing (C) an endomysial
inflammatory infiltrate consisting
mainly of CD68+ macrophages. (D)
Regional upregulation of major his-
tocompatibility complex I (MHC-I)
immunoreactivity at the sarco-
lemma, also with histologically nor-
mal-appearing muscle fibers
showing MHC-I upregulation. Scale
bar = 100 μm.
Neurology.org/N Neurology | Volume , Number  | Month ▪▪, 2019 7
Copyright © 2019 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Figure 4 Visualization and validation of the quantitative proteomics data
(A) Hierarchic clustering analysis (euclidean algorithms) based on the proteomic data of patients A through E and the 3 control individuals. Color codes of the
intensities corresponding to the values that were normalized to the median across the complete dataset are shown below the heat maps. (B) Volcano plot
analysis showing significantly dysregulated proteins (false discovery rate = 0.05, S0 = 0.1) between patients B through E and the 3 control individuals. Vertical
axis corresponds to statistical significance (−log p); horizontal axis shows the average fold change between patients and control individuals (difference in log2
values). (C) Among upregulated or downregulated proteins, PGAM2, LMNB1, and MFF were validated with Western blot analysis. (D) Figures showing iTRAQ
ratios on the left and protein expression data according toWestern blot analysis on the right for PGAM2, LMNB1, andMFF. PC = pooled controls; VCP = valosin-
containing protein gene.
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lower limb muscles being preferentially involved. This patchy
involvement has been described previously and seems to
contrast with the selective patterns of muscle involvement in
muscular dystrophies and sporadic IBM (sIBM).2,20,21
The muscle biopsy of patient A revealed myopathic features
and the presence of atrophic angulated ﬁbers, which are
generally considered a neurogenic feature. However, no di-
agnosis of a lower motor neuron disease (disease of the an-
terior horn cell) or motor neuropathy (axonopathy) could be
made from the clinical and electrophysiologic investigations. This
mixture of myopathic and neurogenic features on muscle biopsy
or on EMG appears to be frequent in VCP-related myopathies.
This observation might suggest the occurrence of a subclinical
Table 3 Bioinformatic interpretation of the proteomics data
Canonical pathways p Value of overlap z Score
Oxidative phosphorylation 3.981E−20 −4.491
Mitochondrial dysfunction 1.259E−19 NaN
Sirtuin signaling pathway 6.310E−17 3
Glycolysis I 3.981E−15 −3.464
Gluconeogenesis I 1.995E−13 −3.317
Epithelial adherens junction signaling 7.586E−10 NaN
Calcium signaling 1.778E−08 0
Actin cytoskeleton signaling 1.905E−08 0.243
Remodeling of epithelial adherens junctions 2.344E−08 NaN
Trichloroacetic acid cycle II (eukaryotic) 1.072E−07 −2.646
Significance A outlier analysis p Value UniProt identifier Protein name
ZFAND1 1.520E−14 Q8TCF1 AN1-type zinc finger protein 1
AK7 3.220E−10 Q96M32 Adenylate kinase 7
RAD17 3.220E−10 O75943 DNA damage checkpoint control protein RAD17
MYH4 6.220E−07 Q9Y623 Myosin-4
WDR33 1.310E−06 Q9C0J8 Pre-mRNA 39 end processing protein WDR33
IGHV3-72 5.240E−06 A0A087WW89 Immunoglobulin heavy variable 3-72
PLN 6.800E−06 P26678 Cardiac phospholamban
LRMP 1.350E−05 Q12912 Lymphoid-restricted membrane protein
MYLK 5.960E−05 Q15746 Myosin light chain kinase, smooth muscle
TNNC1 8.140E−05 P63316 Troponin C, slow skeletal and cardiac muscles
HBB 9.530E−05 P68871 Hemoglobin subunit β
ILF3 1.274E−04 Q12906 Interleukin enhancer-binding factor 2
HBA1 1.997E−04 P69905 Hemoglobin subunit α
CRKL 2.411E−04 P46109 Crk-like protein
MYH1 2.769E−04 P12882 Myosin-1
STK10 2.899E−04 O94804 Serine/threonine-protein kinase 10
MYL2 3.432E−04 P10916 MYL2 protein
TNNT1 4.847E−04 P13805 Troponin T, slow skeletal muscle
NDST1 5.615E−04 P52848 Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1
Abbreviation: NaN = no activity pattern available.
Top: results of the Ingenuity PathwayAnalysis canonical pathway analysis of proteins significantly dysregulated between the 4 patients harboring a heterozygous
mutation in valosin-containing protein gene (VCP) (patients B–E) and 3 control individuals. Filtering based on p value of overlap. Bottom: results of the Significance
A outlier analysis in Perseus comparing protein expression data of patient A and patients harboring a heterozygous mutation in VCP (patients B–E).
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mild motor axonopathy.13,22 Rimmed vacuoles, as observed in
≈35% to 0% of patients exhibiting a VCP-related myopathy
phenotype, have an appearance similar to that of other rimmed
vacuolar myopathies such as sIBM.2 The 15- to 18-nm tubulo-
ﬁlamentous inclusions, which were observed in muscle of patient
A, have previously been observed in muscle of patients with VCP
and are typically also observed in sIBM.13,23 The appearance of
inﬂammatory inﬁltrates and MHC-I upregulation, as observed
for patient A, might further complicate the histopathologic dif-
ferential diagnosis with sIBM.23Onmuscle biopsies of patients C
through E, some endomysial inﬂammatory inﬁltrates were also
observed, with focal invasion of nonnecrotic ﬁbers on muscle
biopsies of patients D and E, but a systematic immunohisto-
chemical study of inﬂammatory features could not be performed
within the scope of this study. According to the literature, the
appearance of inﬂammatory changes on muscle biopsies of
patients manifesting aVCP-relatedmyopathy seems to be rare or
at least not conspicuous, although it has previously been men-
tioned brieﬂy that some biopsies may showMHC-I upregulation
or small inﬂammatory inﬁltrates.2 Focal invasion of nonnecrotic
muscle ﬁbers is typically observed in sIBM and appears to be
a very rare phenomenon in inherited muscle disorders.24
Homozygous mutations in hereditary autosomal-dominant
disorders are uncommon events. Generally, phenotypes are
expected to be more pronounced, but systematic literature is
evidently scarce.25 In case of a direct loss-of-function mech-
anism of the mutation leading to haploinsuﬃciency in the
heterozygous state, a much more severe phenotype is antici-
pated. Dominant-negative mutations, however, are not
expected to cause a much more severe phenotype, and for
mutations exhibiting a gain of function, consequences seem to
be variable.25 In the present case, the index patient exhibited
a typical pattern of muscle weakness. Yet, the onset age of the
myopathy phenotype is rather early for this age-related dis-
order compared to patients harboring the same p.Arg159His
mutation and indeed the complete group of patients with
MSP1; the mean age at onset is ≈40 to 45 years, with few
patients being in their 20s.2,3,8–12,26 Notably, CK levels for the
index patient are markedly elevated (1138 U/L), contrasting
with CK levels generally reported to be normal or mildly
elevated in VCP-related myopathies.3,4 Besides these anom-
alies, the 2 key features of VCP-related disease are preserved,
i.e., the slowly progressive, age-related nature of the disorder
and the tissue-speciﬁc phenotype.1 An example of another
autosomal-dominant age-related disorder for which homo-
zygosity of a known variant appeared to be viable and mod-
erately accelerate the age at onset is familial Alzheimer disease
linked to the E280A mutation in PSEN1.27 Other similar
examples have been described in other protein aggregate
myopathies, i.e., myotilinopathies and desminopathies.28,29
Because of the singularity of the observation of a human patient
with a homozygous VCP mutation, we decided to dissect bi-
ological disease signatures by means of quantitative proteomic
analyses. First of all, hierarchic clustering analyses did not yield
arguments for globally diﬀerent patterns of protein dysregulation
at the level of the proteome between patient A and 4 other
patients with a VCP-related myopathy or between patients har-
boring the p.Arg159His mutation or the p.Gly125Asp mutation.
Functional annotation of proteins signiﬁcantly dysregulated be-
tween heterozygous patients and control individuals yielded
a general appreciation of VCP-related disease signatures in
muscle. Whereas the downstream pathway analysis pointed
mainly toward metabolic failure of skeletal muscle, the upstream
regulator analysis reﬂected a broader landscape of potential
pathomechanisms, including failure of muscle regeneration, ox-
idative stress, endoplasmic reticulum stress, and the unfolded
protein response. Furthermore, the appearance of KDM5A as
a predicted upstream regulator with the highest positive z score
also hinted at involvement of DDR signaling.19 Changes in cel-
lular energy metabolism most likely represent a nonspeciﬁc
downstream consequence of diseasemechanisms in degenerative
muscle disorders, as, for example, also described in a proteomic
study of muscle tissue of patients manifesting a GNE-related
myopathy.30 The focused outlier analysis conducted in the
present study identiﬁed ZFAND1 as the top-scoring diﬀeren-
tially regulated protein when the homozygous patient was
compared with the heterozygous patients. This protein was re-
cently identiﬁed as an evolutionarily conserved regulator of stress
granule turnover that recruits VCP and the 26S proteasome to
organize degradation of stress granules.31 That ZFAND1 appears
to be upregulated in muscle tissue of the homozygous patient
compared to the heterozygous patients most likely indicates
a compensatory mechanism, e.g., because of a more pronounced
loss of interaction with VCP or a marked aggregation of stress
granules. The relevance of stress granules for pathomechanisms
of VCP-related disease had been suggested by the ﬁnding that
C2C12 myoblast cell lines transfected with mutant VCP showed
delayed stress granule resolution on oxidative stress.32 Clinico-
pathologically, there are important similarities between VCP-
related disease and the multisystem proteinopathies related to
mutations in stress granule components such asHNRNPA1 and
HNRNPA2B1, further implicating a strong interconnection of
proteostasis and stress granule homeostasis in disease.31,33
Structural appraisal of the p.Arg159His mutations using VCP
3D models34 supports the hypothesis that this mutation aﬀects
the interactor binding behavior of VCP only subtly. VCP is
assembled as a homohexamer, with each monomer comprising
an N-terminal domain and 2 ATPase domains (D1 and D2).
The D1 and D2 domains are arranged in coaxially stacked rings,
and the N-terminal domains are located at the periphery of the
ring formed by the D1 domains.1 Arg159 locates to the β-barrel
moiety of the N-terminal domain of VCP, and its side chain is
situated in the interface of the N-terminal domain and the D1
domain (residues 155–159, 386, 387). Of >40 reported disease
mutations, 16 map to this interface.2 In general, amino acid
residues located at domain interfaces of complex multidomain
proteins are poised to engage in interdomain communications
either through direct van der Waals or polar interactions or,
more subtly, through allosteric mechanisms. Indeed, recent
NMR-based studies investigating the conformational equilib-
rium of the N-terminal domain of VCP between the “up” (VCP:
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ATP) and “down” (VCP:ADP) states found that residues in this
interface can cause subtle changes to the “up” or “down” equi-
librium, which probably aﬀects the binding behavior of VCP to
its partner proteins.35,36 Visual inspection of the VCP hexamer
fromProteinData Bank entry 1s3second34 indicates that the side
chain of Arg159 possibly engages in 2 interactions of importance,
one with a residue in the same structural moiety (Glu124,
β-barrel moiety of the N-terminal domain) and one with a resi-
due in theD1 domain (Ala232, RecA-likemoiety). Replacing the
side chain of 159 with an imidazolyl (histidine side chain) group
would disrupt both interactions.
The clinical ﬁndings in this homozygous patient, together with
the results of the proteomic analysis and a structural appraisal of
the p.Arg159His mutation, suggest subtle changes of VCP
dynamics and, as a result, altered binding behavior of VCP with
respect to speciﬁc interactors as a likely (dominant-negative)
molecular mechanism for the observed disease pathology. In
particular, the present constellation allows the comparison of
the proteomic consequences of the unique in vivo situation of
having VCP hexamers constituting only mutant VCP mono-
mers rather than a situation of having variable combinations of
wild-type or mutant proteins in diﬀerent VCP hexamers. Thus,
the availability of homozygous and heterozygous patients
presents a highly valuable resource because functional analysis
of mutant VCP protein in vitro is always biased toward full
mutant hexamers.7 However, with our current data, we cannot
experimentally disprove the gain-of-function hypothesis that
has recently been put forward5 based on the observation that
the regulation of ATPase activity may be altered in VCP
mutants.7 The ultimate set of upstream key regulators and key
pathways that are speciﬁcally aﬀected by the VCP p.Arg159His
(or indeed any pathogenic) mutation remains to be unraveled.
Preservation of the age-related nature of the disorder in case of
homozygosity of theVCP p.Arg159Hismutation contrasts with
ﬁndings in the VCP p.Arg155His homozygousmissense mouse
model, which exhibits growth retardation and early lethality
(survival <21 days).37 Other animal models have been used for
preclinical studies of compounds and to study the pathogenesis
of VCP-related disease, of which the heterozygous VCP
p.Arg155His+/− knock-in mouse model seems to mimic the
MSP1 phenotype.38 However, because diﬀerent missense
mutations are being compared, these mouse models should be
used with caution in the study of the molecular mechanisms of
VCP mutations especially considering the striking early-onset
phenotype in the homozygous mice. Directly studying patho-
mechanisms in diseased tissue of patients is therefore highly
relevant. This present study reports a proteomic dataset on
muscle tissue of patients withVCP. Although this study focused
on a relatively small yet relevant set of samples, it serves as
a proof of concept for further investigations of molecular
mechanisms of VCP pathologies.
Clearly, homozygosity of the p.Arg159His mutation in VCP
appears to be viable, and key features of VCP-related disease
are preserved. Notably, the observed phenotype appears to be
slightly more severe than in patients harboring a heterozygous
mutation in VCP. The ﬁndings in this study hint at the complex
molecular mechanisms of VCP-related disease and illustrate the
phenotypic variability and diagnostic pitfalls in MSP1.
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